Advertisement

Teratogenesis and Infection

  • Suzie Wills
Chapter

Abstract

The word teratogenic is derived from the Greek teratos, meaning monster, and genesis, to be born or produced. A teratogenic agent is the one capable of causing birth defects following exposure during pregnancy. Substances with teratogenic qualities include drugs, environmental agents, infections, toxins and nutrients. The probability of a malformation being produced depends on the dose of the agent, the stage at which the embryo is exposed and the genotype of the embryo and the mother.

Further Reading

  1. Beckwith JB. Congenital malformations: from superstition to understanding. Virchows Arch. 2012;461(6):609–19.CrossRefGoogle Scholar
  2. Coll O, Benoist G, Ville Y, Weisman LE, Botet F, Anceschi MM, et al. Guidelines on CMV congenital infection. J Perinat Med. 2009;37(5):433–45.CrossRefGoogle Scholar
  3. Detrait ER, George TM, Etchevers HC, Gilbert JR, Vekemans M, Speer MC. Human neural tube defects: developmental biology, epidemiology, and genetics. Neurotoxicol Teratol. 2005;27(3):515–24.CrossRefGoogle Scholar
  4. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Austr. 1941;3:35–46.Google Scholar
  5. Jones K, Smith D, Ulleland C, Streissguth A. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet. 1973;301(7815):1267–71.CrossRefGoogle Scholar
  6. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database of Systematic Reviews. 2001;(3):CD001056.  https://doi.org/10.1002/14651858.CD001056.
  7. Muralidharan P, Sarmah S, Zhou FC, Marrs JA. Fetal alcohol spectrum disorder (FASD) associated neural defects: complex mechanisms and potential therapeutic targets. Brain Sci. 2013;3(2):964–91.CrossRefGoogle Scholar
  8. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol. 1986;13(3):555–73.CrossRefGoogle Scholar
  9. Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet. 1992;29(10):716–23.CrossRefGoogle Scholar
  10. Vargesson N. Thalidomide embryopathy: an enigmatic challenge. ISRN Dev Biol. 2013;2013:241016, 18 pages.CrossRefGoogle Scholar
  11. Vianna FS, Schuler-Faccini L, Leite JC, et al. Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. Clin Dysmorphol. 2013;22:59–63.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Suzie Wills
    • 1
  1. 1.(Formerly) Royal Hospital for ChildrenGlasgowUK

Personalised recommendations